According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
CLIGF has been the topic of several other research reports. Royal Bank of Canada restated an outperform rating on shares of Clinigen Group in a report on Wednesday, July 7th. Stifel Nicolaus lowered Clinigen Group from a buy rating to a hold rating in a report on Thursday, June 10th.
Clinigen Group Company Profile
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines.
Recommended Story: How do buyers and sellers choose a strike price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.